BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen (Euronext: IPN; ADR: IPSEY) US operations today announced that it completed the appointment of its nine-member US Leadership Team tasked with advancing business and commercialization activities for its specialty medicines, Somatuline® Depot (lanreotide) Injection and Dysport® (abobotulinumtoxinA) for Injection. These medicines treat, respectively, a rare hormonal growth disorder called acromegaly and the debilitating condition of cervical dystonia – orphan conditions each affecting fewer than 250,000 patients.1 The executive appointments follow the recent relocation of Ipsen operations from California to New Jersey – a pivotal part of the Company’s overall US market growth strategy.
